Charlie Michael McLaughlin

Title: Charlie Michael McLaughlin: Innovator in Pharmaceutical Compositions

Introduction

Charlie Michael McLaughlin is a notable inventor based in Bend, Oregon. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions aimed at treating cancer. His innovative work has led to the granting of a patent that showcases his expertise and dedication to improving healthcare.

Latest Patents

McLaughlin holds a patent for pharmaceutical compositions that include N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)-benzamide. This patent focuses on formulations that can be used in dosage forms and methods for treating subjects diagnosed with cancer. His work in this area is crucial for advancing treatment options available to patients.

Career Highlights

Currently, McLaughlin is associated with Ignyta, Inc., a company dedicated to developing targeted therapies for cancer. His role at Ignyta allows him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development.

Collaborations

Some of his notable coworkers include Robert L. Orr and Kathryn Emily Colombo Pugh. Their collective expertise enhances the innovative environment at Ignyta, fostering advancements in cancer treatment.

Conclusion

Charlie Michael McLaughlin's contributions to pharmaceutical compositions exemplify the impact of innovation in healthcare. His patent and work at Ignyta, Inc. highlight his commitment to improving treatment options for cancer patients.